Ellington Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ellington Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-9,300	Closed	-$786K	–	84
2020 Q1	$786K	Buy	9,300 +5,600	+151%	+$483K	0.18%	153
2019 Q4	$313K	Buy	+3,700	New	+$279K	0.07%	294
2019 Q3	–	Sell	-6,100	Closed	-$522K	–	602
2019 Q2	$522K	Buy	+6,100	New	+$522K	0.09%	227
2019 Q1	–	Sell	-2,600	Closed	-$221K	–	564
2018 Q4	$221K	Buy	+2,600	New	+$247K	0.07%	281
2018 Q1	–	Sell	-8,400	Closed	-$749K	–	821
2017 Q4	$749K	Buy	+8,400	New	+$730K	0.12%	134
2014 Q1	–	Sell	-4,000	Closed	-$281K	–	609
2013 Q4	$281K	Buy	+4,000	New	+$272K	0.1%	337

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Ellington Management Group's BMRN Position: Q2 2020 in Review

Ellington Management Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 9,300 shares — an estimated $786K sold.

Ellington Management Group first reported a position in BMRN in Q4 2013 and held it in 6 quarters. The position peaked at $786K in Q1 2020. 528 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Ellington Management Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 9,300 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $786K.
Ellington Management Group first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Ellington Management Group's BioMarin Pharmaceuticals position peaked at $786K in Q1 2020.
528 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.